AU739071C - Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system - Google Patents

Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system

Info

Publication number
AU739071C
AU739071C AU29209/99A AU2920999A AU739071C AU 739071 C AU739071 C AU 739071C AU 29209/99 A AU29209/99 A AU 29209/99A AU 2920999 A AU2920999 A AU 2920999A AU 739071 C AU739071 C AU 739071C
Authority
AU
Australia
Prior art keywords
central nervous
nervous system
transcription
estradiol
oestrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29209/99A
Other versions
AU2920999A (en
AU739071B2 (en
Inventor
Michael Oettel
Vladimir Patchev
Wolfgang Romer
Sigfrid Schwarz
Ina Thieme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/en
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Publication of AU2920999A publication Critical patent/AU2920999A/en
Application granted granted Critical
Publication of AU739071B2 publication Critical patent/AU739071B2/en
Publication of AU739071C publication Critical patent/AU739071C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

Selected steroids are used to produce pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system (CNS) without influencing other organs or systems. These steroids are characterised in that they have a selective, neurotropic, oestrogen-like transcription effect, unlike the systemically active natural and synthetic oestrogens, including 17a-estradiol. It has been surprisingly discovered that the selected steroids, when used according to the invention, selectively influence the transcription of oestrogen-dependent genes in the central nervous system and cause alterations of the corresponding physiological parameters; have transcription effects specific to the central nervous systems in doses which have no biological effects on the tissues of the reproductive system; have transcription effects specific to the central nervous system at doses at which neither 17b-estradiol nor 17a-estradiol have any effect; and do not influence the transcription of oestrogen-dependent genes in the central nervous system to a greater extent than the secondary 17b-estradiol.
AU29209/99A 1998-02-20 1999-02-10 Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system Ceased AU739071C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE19807264 1998-02-20
DE19821831 1998-05-15
DE1998121831 DE19821831A1 (en) 1998-05-15 1998-05-15 Selectively supplementing estrogen deficiency in the central nervous system, using 14,15-cyclopropano estrane steroid compounds
PCT/DE1999/000353 WO1999042108A1 (en) 1998-02-20 1999-02-10 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Publications (3)

Publication Number Publication Date
AU2920999A AU2920999A (en) 1999-09-06
AU739071B2 AU739071B2 (en) 2001-10-04
AU739071C true AU739071C (en) 2002-04-11

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29209/99A Ceased AU739071C (en) 1998-02-20 1999-02-10 Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system

Country Status (24)

Country Link
EP (1) EP1056460B1 (en)
JP (1) JP2002503694A (en)
KR (1) KR20010041107A (en)
CN (1) CN1291102A (en)
AT (1) ATE252388T1 (en)
AU (1) AU739071C (en)
BG (1) BG104689A (en)
BR (1) BR9909205A (en)
CA (1) CA2321498A1 (en)
CZ (1) CZ291764B6 (en)
DE (1) DE59907446D1 (en)
EA (1) EA002707B1 (en)
EE (1) EE03906B1 (en)
HU (1) HUP0100742A3 (en)
ID (1) ID27069A (en)
IL (1) IL137727A0 (en)
IS (1) IS5571A (en)
NO (1) NO20004153L (en)
NZ (1) NZ506049A (en)
PL (1) PL342313A1 (en)
SK (1) SK12152000A3 (en)
TR (1) TR200002400T2 (en)
UA (1) UA57830C2 (en)
WO (1) WO1999042108A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (en) * 2001-11-07 2006-06-01 Schering Ag IN VITRO LIGAND CROSSING OF THE STROGEN RECEIVER.
CN112189624A (en) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) Method for constructing and identifying female AD model by using receptor gene silencing technology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
WO1995012402A1 (en) * 1993-11-05 1995-05-11 University Of Florida Research Foundation, Incorporated Estrogen compositions and method for neuroprotection
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
DE4239946C2 (en) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estrane derivatives with a 14alpha, 15alpha-methylene group and process for their preparation
DE4338314C1 (en) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage
DE4429397C2 (en) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE19524937A1 (en) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage and for drug substitution in men

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
WO1995012402A1 (en) * 1993-11-05 1995-05-11 University Of Florida Research Foundation, Incorporated Estrogen compositions and method for neuroprotection
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
PL342313A1 (en) 2001-06-04
EP1056460B1 (en) 2003-10-22
CN1291102A (en) 2001-04-11
EE200000477A (en) 2001-12-17
KR20010041107A (en) 2001-05-15
AU2920999A (en) 1999-09-06
NZ506049A (en) 2002-09-27
CZ291764B6 (en) 2003-05-14
JP2002503694A (en) 2002-02-05
DE59907446D1 (en) 2003-11-27
BG104689A (en) 2001-04-30
EA002707B1 (en) 2002-08-29
CZ20002938A3 (en) 2001-01-17
WO1999042108A1 (en) 1999-08-26
TR200002400T2 (en) 2000-11-21
EP1056460A1 (en) 2000-12-06
CA2321498A1 (en) 1999-08-26
ATE252388T1 (en) 2003-11-15
NO20004153L (en) 2000-10-09
HUP0100742A3 (en) 2002-07-29
UA57830C2 (en) 2003-07-15
IL137727A0 (en) 2001-10-31
ID27069A (en) 2001-02-22
EA200000858A1 (en) 2001-04-23
IS5571A (en) 2000-07-24
SK12152000A3 (en) 2001-02-12
BR9909205A (en) 2000-11-14
EE03906B1 (en) 2002-12-16
NO20004153D0 (en) 2000-08-18
HUP0100742A2 (en) 2001-09-28
AU739071B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO1998027929A3 (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
HUP0102483A2 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
WO1996019568A3 (en) Stabilized ribozyme analogs
TR199800648A1 (en) Medication system for two or more active ingredients.
NL300381I2 (en) Estradiol valerate and dienogest
MX9700223A (en) Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
AU2561195A (en) Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
AU7496894A (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
AU739071C (en) Pharmaceutical preparations for the selectively supplementing estrogen deficiency in the central nervous system
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
HUP9900612A2 (en) Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
WO2001085165A3 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
EP1003465A4 (en) Prevention/retardation of hair growth
AU2691197A (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
AU8624198A (en) 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments.
WO2002022645A3 (en) Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
Cadman Roche brings new formulation of saquinavir to FDA. Food and Drug Administration
DE59507710D1 (en) DIPEPTIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
AU6923494A (en) Orally administerable esters of 14alpha,15alpha-methylene-oestradiol with an oestrogenic action
三木保 et al. Neuro-Endoscopic Antomy of The Posterior Fossa
MX9606041A (en) Fast dissolving dosage forms.

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010911

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20011018

MK14 Patent ceased section 143(a) (annual fees not paid) or expired